A dual efficacy-implementation trial of a novel mobile application for childhood nephrotic syndrome management: the UrApp for childhood nephrotic syndrome management pilot study protocol (UrApp pilot study)
Open Access
- 9 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Nephrology
- Vol. 21 (1), 1-9
- https://doi.org/10.1186/s12882-020-01778-w
Abstract
Idiopathic nephrotic syndrome has a relapsing-remitting course in the majority of pediatric patients, demanding vigilant monitoring and self-management. A novel, expert-designed, user-informed mobile application (app), UrApp©, was created to support management tasks, including home urine protein monitoring. The UrApp Pilot Study (ClinicalTrials.gov, NCT04075656) is a randomized trial comparing UrApp-supported nephrotic syndrome management with standard-of-care with parallel process evaluation of the intervention delivery. Sixty caregivers of children with newly diagnosed, steroid-sensitive nephrotic syndrome will be randomized 1:1 to UrApp-supported care or standard-of-care. Follow-up will be 1 year, with primary outcomes of adherence to urine monitoring and medications assessed at 6 and 12 months. Secondary outcomes at 6 and 12 months include self-efficacy, quality-of-life, hospitalizations and delayed relapse diagnoses. A mixed-methods approach will evaluate UrApp engagement, use retention, features used, user perceptions, and contextual barriers and facilitators of UrApp use. User behavior will be assessed for relationships to the primary and secondary outcomes. A Stakeholder Committee of volunteer trial participants, clinicians, and engineers will examine the trial results and design a pragmatic UrApp-enhanced nephrotic syndrome intervention with potential for wide implementation. The final UrApp intervention will be tested in a user-centered hybrid effectiveness-implementation trial designed with stakeholder input. The UrApp Pilot Study examines the efficacy of a novel app designed specifically for nephrotic syndrome. The protocol involves dual efficacy and process evaluation aims to increase efficiency and incorporates the stakeholders’ perspective in formative assessment to inform intervention redesign and the design of a future user-centered trial. ClinicalTrials.gov, NCT04075656. Registered on September 2, 2019, https://clinicaltrials.gov/ct2/show/NCT04075656Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK118189)
This publication has 17 references indexed in Scilit:
- Development of a novel mobile application to detect urine protein for nephrotic syndrome disease monitoringBMC Medical Informatics and Decision Making, 2019
- Text Messaging for Disease Monitoring in Childhood Nephrotic SyndromeKidney International Reports, 2019
- Childhood Nephrotic Syndrome Management and Outcome: A Single Center Retrospective AnalysisInternational Journal of Nephrology, 2017
- Learning to live with nephrotic syndrome: experiences of adult patients and parents of children with nephrotic syndromeNephrology Dialysis Transplantation, 2017
- Inpatient Health Care Utilization in the United States Among Children, Adolescents, and Young Adults With Nephrotic SyndromeAmerican Journal of Kidney Diseases, 2013
- Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGOPediatric Nephrology, 2012
- Childhood nephrotic syndrome—current and future therapiesNature Reviews Nephrology, 2012
- Nephrotic syndrome in childhoodThe Lancet, 2003
- Primary nephrotic syndrome in children: Clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularityKidney International, 1981
- The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone: A report of the international study of kidney disease in childrenThe Journal of Pediatrics, 1981